this is very fair. We are certainly early to this story and what...

this is very fair. We are certainly early to this story and what we think there are initial indications off funds will want to see inked in results
- continued growth qtr on qtr
- CF+

but when your early and right with decent position size great things can happen.

The natural flip side is dealing with volatility and not letting negative opinions thrown from the sidelines distract from real company analysis

one of the big concentration risks which will put off funds is not so much the single product (didn’t bother cochlear/ resmed / nanosonics etc) but the lack of country diversification and reliance on US revenue and hence funding / reimbursement changes risk even though now we are seeing this swing to the positive with new proposed fee increases.

I’m convinced once the early stage growth and take up we have evidence of in other countries proves this to be a global best in class growth story and further dervish’s US reliance that will also be a turning point. In only the last few months we have seen new surgeries, sales and public health take upin
- South America
- Portugal
- UK
- Canada
- Spain
- Germany
- UAE
- Pakistan
- Singapore
- South Korea approval pending
- China approval pending
- Aus surgeons are using this today and anyone feeling your vision needs a check up get it done